|
PARP4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.818350E-02 |
| Normal-vs-Stage3 |
2.70816702396814E-12 |
| Normal-vs-Stage4 |
1.85510495853691E-11 |
| Stage1-vs-Stage2 |
5.581700E-03 |
| Stage1-vs-Stage3 |
5.296200E-01 |
| Stage1-vs-Stage4 |
7.509800E-02 |
| Stage2-vs-Stage3 |
2.134200E-02 |
| Stage2-vs-Stage4 |
2.385700E-04 |
| Stage3-vs-Stage4 |
2.558000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.398600E-04 |
| Normal-vs-Asian |
3.37659999960493E-07 |
| Caucasian-vs-AfricanAmerican |
7.792400E-01 |
| Caucasian-vs-Asian |
3.108800E-01 |
| AfricanAmerican-vs-Asian |
6.468600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.79221090693227E-13 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.909600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
7.50199999899337E-08 |
| Normal-vs-Age(81-100Yrs) |
6.558500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.498400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.443900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.396300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.029200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.008800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.120400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.806000E-01 |
| Classical-VS-Follicular |
1.24344978758018E-14 |
| Classical-VS-Other |
2.231200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
5.34970000520829E-08 |
| Tall-VS-Other |
2.448600E-01 |
| Tall-VS-Normal |
1.18489995593052E-10 |
| Follicular-VS-Other |
2.026400E-01 |
| Follicular-VS-Normal |
1.282770E-01 |
| Other-VS-Normal |
2.030000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.61579638557896E-11 |
| Normal-vs-N1 |
4.81270023833247E-10 |
| N0-vs-N1 |
4.275700E-02 |
|
|
